Skip to content

Effects of galvanic vestibular stimulation on mood symptoms in Alzheimer's dementia

The effects of galvanic vestibular stimulation on depression and anxiety symptoms in patients with Alzheimer's dementia

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT20170808035571N2
Enrollment
3
Registered
2026-02-12
Start date
2026-02-20
Completion date
Unknown
Last updated
2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer disease. Alzheimers disease

Interventions

Intervention group: Galvanic vestibular stimulation: The electrical noise current with an intensity of 2 mA is delivered by a free-axis battery-powered stimulator through a pair of 5 x 5 cm electrodes

Sponsors

University of social welfare and rehabilitation sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
65 Years to No maximum

Inclusion criteria

Inclusion criteria: Being over 65 years of ageNot taking antidepressants or anti-anxiety medications or taking them at a fixed dose for at least 2 weeks at the screening visit6. Not taking or taking a fixed dose of anti-dementia medications (donepezil, rivastigmine, galantamine, and memantine) for at least 4 weeks at the screening visit7. Not receiving occupational therapy and cognitive rehabilitation interventions8. Not meeting the criteria for vestibular disorder, which is determined by a score of less than 29 on the DHI questionnaire.9. Having a diagnosis of mild Alzheimer's disease based on the opinion of the center's attending physician Having the criteria for probable Alzheimer's disease defined by the National Institute of Neurological and Communicable Diseases and Stroke-Alzheimer's and Related Diseases Research Criteria (NINCDS-ADRDA) Meeting the criteria for depression in Alzheimer's disease defined by the National Institute of Mental Health (NIMH) criteria Not taking antidepressants or anti-anxiety medications or taking them at a fixed dose for at least 2 weeks at the screening visit Not taking fixed dose of anti-dementia medications (donepezil, rivastigmine, galantamine, and memantine) for at least 4 weeks at the screening visit Not receiving occupational therapy and cognitive rehabilitation interventions Not meeting the criteria for vestibular disorder, which is determined by a score of less than 29 on the DHI questionnaire Having a caregiver who lives with the person for at least 10 hours a week to report symptoms Ability to communicate and speak and understand Persian Having an MMSE score below 24

Exclusion criteria

Exclusion criteria: The patient's cognitive impairment is explained by another disease such as cerebral infarction, Parkinson's disease, multiple sclerosis, and normal blood pressure hydrocephalus according to the opinion of the attending physician History of epilepsy Current treatment with antipsychotic drugs Immediate risk of suicide or severe depression and the need for hospitalization in psychiatric units . History of electroconvulsive therapy (ECT) or non-invasive methods of brain stimulation Having contraindications to receiving galvanic atrial stimulation, such as having tattoos or metal on the scalp or brain Current treatment with benzodiazepines or antiepileptic drugs Obtaining a score of less than 10 on the Mini-Mental State Examination (MMSE) Obtaining a score of less than 6 on the 15-item Geriatric Depression Scale (GDS) Having hallucinations and delusions

Design outcomes

Primary

MeasureTime frame
Depression: Participants' score on the Geriatric Depression Scale (GDS). Timepoint: The measurement periods are before the first GVS session, immediately after the last session, and one month after the last session. Method of measurement: Geriatric Depression Scale (GDS).

Secondary

MeasureTime frame
Anxiety: Participants' scores on the Geriatric Anxiety Inventory (GAI). Timepoint: Before the first GVS session, immediately after the last session, and one month after the last session. Method of measurement: Geriatric Anxiety Inventory (GAI).

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMahsa Rohani Anaraki

University of social welfare and rehabilitation sciences

ma.rohani@uswr.ac.ir+98 31 3661 1532

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Jun 11, 2026